---
title: "Surrozen jumps 99% on FDA clinical trial filing for SZN-8141 eye therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300067811.md"
description: "Surrozen surged 99% after filing an FDA clinical trial application for SZN-8141, a dual-mechanism therapy for diabetic macular edema."
datetime: "2026-09-24T18:57:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300067811.md)
  - [en](https://longbridge.com/en/news/300067811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300067811.md)
generator: "portal-rs"
---

# Surrozen jumps 99% on FDA clinical trial filing for SZN-8141 eye therapy

Surrozen(SRZN.US) 盘中涨 98.95%，现报**32.15 美元**。

公司向 FDA 提交 SZN-8141 的临床试验申请，该疗法结合 Wnt 通路激活与 VEGF 抑制双机制，靶向糖尿病性黄斑水肿。患者招募预计于 2026 年底启动，初步结果 anticipated 于 2027 年底公布。

该股被列为当日重点关注的生物制药股之一，市场交投活跃。

### Related Stocks

- [SRZN.US](https://longbridge.com/en/quote/SRZN.US.md)

## Related News & Research

- [Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial](https://longbridge.com/en/news/300788834.md)
- [SRZN: Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease](https://longbridge.com/en/news/299223813.md)
- [Will HDDs Be Replaced by SSDs? Investment Value Analysis of Seagate Technology and Western Digital in the AI Era](https://longbridge.com/en/news/300838673.md)
- [Constellation Brands Stock Forecast: Beer Demand Faces a Key Q2 Earnings Test](https://longbridge.com/en/news/300859275.md)
- [If I Could Only Buy 1 Space Stock for the Next Decade, It Wouldn't Be SpaceX or Rocket Lab](https://longbridge.com/en/news/300850222.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**